Global data highlights effectiveness of romosozumab

Studies show improved bone mineral density and healthcare cost reductions

New data from multiple countries confirm the effectiveness of romosozumab, the dual-acting osteoporosis treatment that increases bone formation and decreases bone resorption. Findings were presented at WCO-IOF-ESCEO 2025 in Rome.

A systematic literature review identified 362 records from 67 studies across 10 countries. Results showed romosozumab significantly improved bone mineral density at 12 months in lumbar spine, total hip and femoral neck studies. Treatment-naïve patients experienced greater gains than previously treated patients.

Prof Bente Langdahl, lead study investigator, said: “Treating patients at high fracture risk with romosozumab at the right time plays a crucial role in strengthening bones and significantly reducing fracture risk.”

UCB expanded the real-world evidence base with additional studies. A retrospective analysis in Germany found patient costs remained stable in the first year of romosozumab treatment, with a significant reduction in the second year, suggesting long-term cost-effectiveness.

A Swedish registry study revealed that 76.9% of patients treated with romosozumab were treatment-naïve, reflecting its adoption as a first-line approach. A claims data analysis in Germany found gaps in osteoporosis treatment, with many high-risk women left untreated, leading to more secondary fractures.

Emmanuel Caeymaex, UCB’s Chief Commercial Officer, said: “The growing body of real-world evidence behind romosozumab reinforces our commitment to bringing meaningful benefits to patients and gives healthcare professionals confidence in its impact.”

Romosozumab was approved in the EU in December 2019 for treating severe osteoporosis in postmenopausal women at high fracture risk. Research continues to strengthen its position in osteoporosis management. Let me know if you’d like further refinements